Multiply Labs, a San Francisco company that builds robots to manufacture advanced medicines, has raised a $75m Series B round led by Dr. Patrick Soon-Shiong and NantWorks, the healthcare and technology group he founded. The round was announced on 6 October 2026.
New investors AstraZeneca, Lingotto, Teradyne and Strange Ventures joined the round, while Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund invested again. The company said its total funding now exceeds $100m. It did not disclose a valuation.
“The world of physical AI biological manufacturing has arrived.”Dr. Patrick Soon-Shiong, Founder, NantWorks
What Multiply Labs does
Founded in 2016, Multiply Labs makes robotic systems that automate complex biologics manufacturing. According to Pharma Manufacturing, its four-arm robotic clusters handle timed and repetitive steps, can run several instruments in parallel and work with the instruments and processes manufacturers already use, so they can be installed in existing facilities without changing validated production methods.
The company started with cell and gene therapies and is now expanding into antibodies, viral vectors and mRNA. Drug makers own and run the systems themselves rather than outsourcing production to Multiply Labs, Pulse 2.0 reported.
Multiply Labs says its systems cut the cost per dose by 74% and deliver up to 100 times the throughput of manual manufacturing, while reducing the risk of contamination from manual handoffs. Those are the company's own figures.
Who invested
AstraZeneca's investment follows a collaboration the two companies began in January 2026 to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing, including end-to-end automation with industry-standard instruments, Pharma Manufacturing reported.
Co-founder and chief executive Fred Parietti said AI is now designing more therapies than the industry will ever be able to manufacture, and that the funding would let the company build capacity to close that gap. Ileana Pirozzi of Lingotto Innovation said she believes robotics can do for biomanufacturing what it did for the automotive and semiconductor industries.
What the money is for
Multiply Labs said it will use the funds to expand manufacturing capacity, speed up its product roadmap and grow its engineering, regulatory and commercial teams. Pharma Manufacturing reported that the company is moving from clinical-stage deployments towards commercial-scale production.
Parietti said the money would let the company build capacity so that more of the patients who need these treatments can get them. The company did not disclose its headcount.
The company so far
Multiply Labs' founding team met at MIT through a shared interest in robots, according to a 2024 company release. HLTH reported that the company first automated the production of personalised dietary supplements and pharmaceutical capsules before moving into advanced therapies.
In May 2024 it signed a commercial and supply agreement worth up to $85m with Retro Biosciences to automate Retro's cell therapy manufacturing for age-related diseases, which the company described as the first commercial sale of its robotic system. It has also listed collaborations with instrument makers and service providers including Cytiva, Thermo Fisher Scientific and Charles River.
HLTH reported that Multiply Labs raised a $20m Series A in 2021 and named Cellares, which sells integrated manufacturing and quality-control systems, as a competitor in automated cell therapy manufacturing. Including the Series B, the company has raised more than $100m since it was founded.
Company website: multiplylabs.com